secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-08-13T20:05:16+00:00
Accession:  0001193125-26-349141
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio Q2 2026 net income $12M vs year-ago loss; cash $95.7M, runway to 2028
--------------------------------------------------------------------------------

- Net income from continuing ops $12.0M ($2.96/share) vs net loss $13.7M ($3.38/share) in Q2 2025.
- Total revenue from continuing ops was negative $1.5M vs positive $1.3M in Q2 2025.
- Cash, cash equivalents, investments, and accounts receivable $95.7M as of June 30, 2026; expected to fund operations into 2028.
- FG-3246 Phase 2 interim analysis in mCRPC on track for 4Q 2026; roxadustat Phase 3 protocol finalized, initiation targeted 4Q 2026.
- New MATTERHORN post hoc data at EHA 2026 showed transfusion independence benefit in LR-MDS with HTB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/0001193125-26-349141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer